The latest call
FetchingSTAAR Surgical Co reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
STAA · Nasdaq · Healthcare · Medical Instruments and Supplies
$26.39-1.5%Nov 13 close
Figures through October 2, 2026, from the 10-Q filed November 4, 2026
Just reported
From STAAR Surgical Co's results release of November 4, 2026; its quarterly report has since been filed.
Actual
$83.4M
-12% y/y
-11% q/q
Guided
—
No guide given
Actual
$0.11
-39% y/y
-31% q/q
Guided
—
No guide given
| Measure | 3 months toOct 2, 2026 | 3 months toSep 26, 2025 | Change |
|---|---|---|---|
| Total Revenue | $83.4M | $94.7M | -11.95% |
| Profit | $5.6M | $8.9M | -37.25% |
| Profit per share | $0.11 | $0.18 | -38.89% |
| Free Cash Flow | $26.4M | $1.8M | +1,378.70% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
STAAR Surgical Co reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Our record nine-month performance keeps us firmly on track to deliver strong full-year GAAP net income with free cash flow and a debt-free balance sheet,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from STAAR Surgical Co’s Item 2.02 8-K filed November 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Actual
$5.5M
-70% y/y
-46% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.